Leppert JT - Search Results

1

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Klatte T, et al. Among authors: leppert jt. Clin Cancer Res. 2007 Dec 15;13(24):7388-93. doi: 10.1158/1078-0432.CCR-07-0411. Clin Cancer Res. 2007. PMID: 18094421

2

Surveillance following radical or partial nephrectomy for renal cell carcinoma.

Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Lam JS, et al. Among authors: leppert jt. Curr Urol Rep. 2005 Feb;6(1):7-18. doi: 10.1007/s11934-005-0062-x. Curr Urol Rep. 2005. PMID: 15610692 Review.

3

Novel approaches in the therapy of metastatic renal cell carcinoma.

Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Lam JS, et al. Among authors: leppert jt. World J Urol. 2005 Jul;23(3):202-12. doi: 10.1007/s00345-004-0466-0. Epub 2005 Apr 5. World J Urol. 2005. PMID: 15812574 Review.

4

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Lam JS, et al. Among authors: leppert jt. J Urol. 2005 Jun;173(6):1853-62. doi: 10.1097/01.ju.0000165693.68449.c3. J Urol. 2005. PMID: 15879764 Review.

5

Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.

Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Lam JS, et al. Among authors: leppert jt. J Urol. 2005 Aug;174(2):466-72; discussion 472; quiz 801. doi: 10.1097/01.ju.0000165572.38887.da. J Urol. 2005. PMID: 16006866

6

Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.

Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Leppert JT, et al. BJU Int. 2005 Aug;96(3):281-5. doi: 10.1111/j.1464-410X.2005.05615.x. BJU Int. 2005. PMID: 16042714

7

Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.

Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Lam JS, et al. Among authors: leppert jt. BJU Int. 2005 Sep;96(4):483-8. doi: 10.1111/j.1464-410X.2005.05670.x. BJU Int. 2005. PMID: 16104896 Review. No abstract available.

8

Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.

Leppert JT, Lam JS, Belldegrun AS. Leppert JT, et al. J Immunother. 2005 Sep-Oct;28(5):427-9. doi: 10.1097/01.cji.0000170358.92090.c2. J Immunother. 2005. PMID: 16113598 No abstract available.

9

Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.

Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Lam JS, et al. Among authors: leppert jt. Urology. 2005 Nov;66(5 Suppl):1-9. doi: 10.1016/j.urology.2005.06.112. Urology. 2005. PMID: 16194700 Review.

10

Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery.

Dave DS, Lam JS, Leppert JT, Belldegrun AS. Dave DS, et al. Among authors: leppert jt. BJU Int. 2005 Dec;96(9):1268-74. doi: 10.1111/j.1464-410X.2005.05834.x. BJU Int. 2005. PMID: 16287443 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters